General Proximity De-Stealths with $16M to Pioneer Next-Gen Induced Proximity Medicines for ‘Undruggable’ Targets
The company will use the capital to accelerate the development of treatments targeting undruggable proteins associated with cancer, cardiometabolic disease,…
